Aastrom Biosciences, the Ann Arbor, MI-based developer of cell therapies for cardiovascular diseases, is presenting some new data on a clinical trial of its method against critical limb ischemia, a complication of clogged arteries that often leads to amputation and death. Detailed results from half of the first 90 patients are being presented today at the Society of Vascular Surgery meeting in Boston. Aastrom (NASDAQ: [[ticker:ASTM]]) is hosting a conference call to discuss the results today at 3:30 pm Eastern time. We profiled the company earlier this month.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
